Citadel Advisors »

Karyopharm Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.8M 508k 5.57
2025-12-31 $997k 136k 7.36
2025-09-30 $602k 92k 6.54
2025-06-30 $961k 223k 4.31
2025-03-31 $828k 221k 3.74

More positions owned by Citadel Advisors

State Str Spdr S&p 500 Etf T Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
NVIDIA Corporation Call Option (NVDA)
Tesla Motors Call Option (TSLA)
Spdr Gold Tr Gold Shs Call Option (GLD)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
Micron Technology Call Option (MU)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Netflix Call Option (NFLX)
Broadcom Call Option (AVGO)
Alphabet Cap Stk Cl C Call Option (GOOG)

View all positions for Citadel Advisors

Top funds holding Karyopharm Therapeutics

Ikarian Capital
Commodore Capital
RA Capital Management
T. Rowe Price Investment Management
Goldman Sachs Group
Catalio Capital Management
Affinity Asset Advisors
Susquehanna International
Boothbay Fund Management
Squadron Capital Management
Vanguard Capital Management
Jane Street
Vanguard Group
Millennium Management
Citadel Advisors

View all funds holding Karyopharm Therapeutics